The present invention relates to methods of treating a cancer and in particular a B-cell derived cancer using a lymphocytotoxic but hematopoeitic cell sparing high-dose pulsed amount of an oxazaphosphorine drug in combination with immune therapeutics such as for example an autologous idiotypic vaccine and monoclonal antibodies that selectively bind B-cell specific antigens.

This invention discloses a solvent-free process for the preparation of cyclophosphamide. According to this invention there is no solvent used during the reaction step for preparing cyclophosphamide so that the total volume of the reaction for preparing cyclophosphamide can be reduced and the manufacture of cyclophosphamide can become more efficient. Furthermore the above solvent-free process for the preparation of cyclophosphamide is more simply operated more economic and more environmental frie...

This invention discloses a solvent-free process for the preparation of cyclophosphamide. According to this invention, there is no solvent used during the reaction step for preparing cyclophosphamide, so that the total volume of the reaction for preparing cyclophosphamide can be reduced and the manufacture of cyclophosphamide can become more efficient. Furthermore, the above solvent-free process for the preparation of cyclophosphamide is more simply operated, more economic, and more environmental...

The present invention is directed to a pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC)

The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the BLyS and/or APRIL antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof a BAFF-R-Fc-fusion protein comprising the extracellular domain of BAFF-R or a functional fragment thereof or a BCMA-Fc-fusion protein compris...

New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I Formula I.1 Formula I.2 Formula IA Formula IB Formula IC and Formula II and their pharmaceutical acceptable salts for the treatment of cancer. The use of a combination of two of these compounds is described and the use of the combination of one of these compounds with an anticancer agent such as decarbazine doxorubicin daunorubicin cyclophosphamide busulfex busulfan vinblastine vincristine bleomycin e...

New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I Formula I.1 Formula I.2 Formula IA Formula IB Formula IC and Formula II and their pharmaceutical acceptable salts for the treatment of cancer. The use of a combination of two of these compounds is described and the use of the combination of one of these compounds with an anticancer agent such as decarbazine doxorubicin daunorubicin cyclophosphamide busulfex busulfan vinblastine vincristine bleomycin e...